Last month in Redwood Shores, Calif., participants in the National Conference of Biotechnology Ventures decided to have some fun. Venture capitalists and biotech CEOs lined up to play a corporate version of "Family Feud," an old television game show in which competing families guessed at trivia.
HIGH HOPES: Venture capitalists want functional genomics firms to partner with drug companies, says Karl Thiel.
Their answer doesn't surprise investment analysts. "Every company having anything to do with genomics is now renaming itself a 'functional genomics' company," declares Stelios Papadopoulos, head of the health care investment banking group at PaineWebber Group Inc. in New York. He notes that...